BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

70.54
EUR
0.00
(0.00%)
-2.61EPS
11.45BMarket Cap
Feb 25Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.39
0.07
0.48
0.53
0.06
1.19
2.62
4.85
Basic EPS, GAAP
-0.33
-1.42
-2.48
-3.8
-3.9
-3.26
-3.95
-2.88
-3.78
-3.04
Free Cash Flow per Basic Share
-0.44
-1.68
-2.44
-3.45
-3.78
-2.89
-3.25
-2.85
-2.38
-1.9
Dividend per Share
0.01
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.49
2.62
3.3
0.47
-5.91
-8.33
-7.73
-7.72
-10.71
-13.29
Tangible Book Value per Share
-0.49
2.62
3.3
0.47
-6.21
-8.52
-7.89
-7.85
-10.86
-13.42
Basic Weighted Avg Shares
92
92
105
118
144
147
163
186
192
195
Sales/Revenue/Turnover
- -
- -
41
8
70
78
9
222
502
946
Operating Margin (%)
- -
- -
-656.41
-5,751.99
-827.12
-603.28
-6,443.56
-260.19
-100
-37.34
Depreciation Expense
- -
- -
1
1
6
7
6
6
5
5
Net Income, GAAP
-31
-131
-261
-449
-563
-481
-643
-536
-725
-566
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-642.47
-5,439.74
-806.9
-619.7
-6,913.92
-241.44
-144.39
-59.84
Working Capital
89
413
508
547
754
427
334
566
510
1,067
LT Debt
- -
55
92
491
1,721
1,720
1,736
1,726
1,856
1,944
Total Equity
-55
377
476
108
-866
-1,245
-1,343
-1,458
-2,077
-1,654
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-72.05
-192.44
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
552
551
550
LT Borrowings
1,926
1,928
1,929
LT Finance Leases
14
15
15
Preferred Equity and Hybrid Capital
- -
- -
942
Shares Outstanding
196
195
196
Market Capitalization
14,582
14,493
12,983

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,241
1,093
2,045
Cash, Cash Equivalents & STI
940
720
1,539
Accounts Receivable, Net
205
254
375
Inventories
33
53
60
Total Current Liabilities
816
891
977
Payables & Accruals
198
255
319
ST Debt
552
551
550
Deferred Revenue
6
6
5

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-159.92%
42.46%
Free Cash Flow
- -
4.49%
-14%
Net Income, GAAP
- -
12.64%
35.31%
Sales/Revenue/Turnover
- -
616.01%
126.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
211
2
3
6
222
2025
117
111
121
154
502
2026
195
244
353
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.39
-0.86
-1.4
-2.88
2025
-0.88
-0.95
-0.95
-1
-3.78
2026
-0.84
-0.78
-0.42
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Neil Kumar
Full Time Employees
839
Sector
Health technology
Industry
Biotechnology
Address
3160 Porter Drive Palo Alto CA United States 94304
IPO Date
Jun 27, 2019
Business
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines to patients with genetic diseases and cancers. The company’s core products and services include the research, development, and commercialization of novel drug candidates targeting genetic disorders and oncology indications. BridgeBio’s portfolio encompasses multiple clinical and preclinical programs across areas such as rare diseases, oncology, and precision medicine, featuring therapies in pipeline development as well as marketed products. BridgeBio operates primarily in the United States but also engages in global clinical trials and partnerships to expand its reach. Founded in 2015 and headquartered in Palo Alto, California, the company leverages its drug development expertise through subsidiaries and strategic alliances with academic institutions, pharmaceutical companies, and biotechnology firms. Recent major company developments include significant funding rounds to advance its pipeline programs; strategic partnerships to enhance its research capabilities; acquisitions aimed at broadening its therapeutic areas and bolstering its technology platforms; and the launch of new investigational drugs targeting underserved genetic conditions. These moves have reinforced BridgeBio’s commitment to advancing precision medicine and expanding its impact in the rare disease and oncology markets. The company continues to evolve its pipeline with a focus on rapid clinical development and commercialization of targeted therapies to improve patient outcomes.

Company News

  • BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

  • BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026

  • BridgeBio to Participate in November and December Investor Conferences

  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

  • Should You Invest $1,000 in BridgeBio Pharma Right Now?

  • BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript

  • What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call

  • BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

  • BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

  • BridgeBio Pharma Q3 2026 Earnings Call Transcript

  • BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates

  • BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

  • 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)

  • BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

  • Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

  • FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing